Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionKestra Advisory Services, LLC
Latest Disclosed Ownership13,950 shares
Latest Disclosed Value $ 6,229,121
Kestra Advisory Services, LLC reports 3.33% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 30, 2026 - Kestra Advisory Services, LLC filed a 13F-HR form disclosing ownership of 13,950 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $6,229,233 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 14,431 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -3.33% during the quarter. The current value of the position is $6,233,278 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,950 -481 -3.33 6,229 -4.78 0.0236
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,431 40 0.28 6,542 16.08 0.0269
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,391 33 0.23 5,636 -11.83 0.0258
2025-08-15 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,358 1,148 8.69 6,392 -0.19 0.0312
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,210 -3,048 -18.75 6,404 -2.18 0.0310
2025-02-10 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,258 -513 -3.06 6,547 -16.05 0.0358
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,771 -2,973 -15.06 7,800 -15.72 0.0430
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,744 -697 -3.41 9,254 8.31 0.0517
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 20,441 2,425 13.46 8,544 16.56 0.0573
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,016 2,245 14.23 7,331 33.66 0.0594
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,771 464 3.03 5,484 1.82 0.0539
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,307 3,110 25.50 5,387 40.15 0.0539
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,197 -9,768 -44.47 3,843 -39.41 0.0417
2023-01-31 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,965 2,761 14.38 6,343 126,760.00 0.0564
2022-11-01 2022-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 19,204 -2,822 -12.81 6 -16.67 0.0595
2022-11-01 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,204 -2,822 5,560 0.0595
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 22,026 -2,371 -9.72 6 0.00 0.0638
2022-07-20 2022-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 24,397 5,720 30.63 6 50.00 0.0663
2022-04-26 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,397 5,720 6,367 0.0663
2022-07-25 2021-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 18,677 -1,802 -8.80 4 33.33 0.0415
2022-01-20 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,677 -1,802 4,101 0.0415
2022-07-25 2021-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 20,479 -2,320 -10.18 4 -25.00 0.0371
2021-10-19 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,479 -2,320 3,715 0.0371
2022-07-26 2021-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 22,799 -948 -3.99 5 -20.00 0.0522
2021-07-28 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 22,799 -948 4,597 0.0522
2022-07-27 2021-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 23,747 18,503 352.84 5 400.00 0.0648
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,747 18,503 5,103 0.0648
2022-07-28 2020-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,244 5,158 5,997.67 1 -100.00 0.0141
2021-01-20 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,244 5,158 1,220 0.0141
2022-07-29 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 86 86 1,452,000 0.0271
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 86 86 1,452 0.0271
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.